Services on Demand
Arquivos Brasileiros de Endocrinologia & Metabologia
On-line version ISSN 1677-9487
DONANGELO, Ines; UNE, Karina and GADELHA, Mônica. Diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metab [online]. 2003, vol.47, n.4, pp. 331-346. ISSN 1677-9487. http://dx.doi.org/10.1590/S0004-27302003000400006.
Acromegaly is a disabling and disfiguring illness, which, if not adequately controlled, decreases life expectancy. Cardiovascular and respiratory complications represent the main causes of death in acromegalic patients. Nowadays, the diagnosis is made following the guidelines reported in the 2000 consensus: Failure of GH to suppress to less than 1ng/mL and an increased IGF-1. Progress in all therapeutic modalities has been made, allowing biochemical disease control in more patients. Previous studies demonstrated that achieving safe GH levels (mean GH <2.5ng/mL) and normal IGF-1 decreases mortality rate to normal. In 2002, the guidelines for management of acromegaly were published which encompass, many times, a multidisciplinary approach. In this article, we critically evaluate what is available in Brazil that allows us to follow the guidelines established in the diagnosis and treatment consensus.
Keywords : Acromegaly; Diagnosis; Transsphenoidal surgery; Radiotherapy; Somatostatin analog; Dopamine agonist.